Nicotinamide Riboside (NR): Evidence, Dosing, and Longevity Applications

What Is Nicotinamide Riboside and Why Does NAD+ Matter?

Nicotinamide riboside is a naturally occurring form of vitamin B3 found in trace amounts in milk and yeast. The body converts it to nicotinamide adenine dinucleotide (NAD+), a coenzyme required for over 500 enzymatic reactions, including mitochondrial energy production, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation. NAD+ blood levels fall roughly 50% between young adulthood and age 60, a decline documented across tissues in both rodents and humans. [1]

That decline matters clinically. Sirtuins (SIRT1 through SIRT7) depend on NAD+ as a required co-substrate. When NAD+ drops, sirtuin activity drops with it, slowing the deacetylation of proteins that govern inflammation, mitochondrial biogenesis, and DNA damage checkpoints. [2] PARP1, the primary DNA-nick repair enzyme, similarly consumes NAD+ at a rate that accelerates after oxidative injury, creating a potential cycle where aging tissue both produces more DNA damage and has less NAD+ available to repair it. [3]

The salvage pathway converts nicotinamide riboside to NMN (nicotinamide mononucleotide) via NRK1 and NRK2 kinases, and then to NAD+ via NMNAT enzymes. This is a distinct entry point from the tryptophan de novo pathway and from plain nicotinamide, which means NR can raise NAD+ even when those upstream routes are saturated. [4]

Human Pharmacokinetic and Dosing Evidence

A 2018 phase I dose-escalation trial by Trammell et al. (N=12) established that single oral doses of NR chloride at 100 mg, 300 mg, and 1 to 000 mg all produced dose-dependent rises in blood NAD+ metabolites within two hours, with the 1 to 000 mg dose increasing whole-blood NAD+ by approximately 2.7-fold over baseline. [5] That data gave clinicians the first human pharmacokinetic map for NR.

The Martens et al. 2020 randomized controlled trial (N=120, age 55, 79) is the largest independent NR study published to date. Participants received 500 mg NR twice daily (1 to 000 mg/day total) or placebo for six weeks. Whole-blood NAD+ rose 68% in the NR group vs. 0.1% in placebo (P<0.001). [6] Systolic blood pressure fell by a mean of 3.9 mmHg and aortic stiffness trended lower, though the study was not powered to confirm cardiovascular endpoints. No serious adverse events occurred.

A 2023 trial in healthy older adults (N=40) by Mehmel et al. tested 300 mg/day for 12 weeks. NAD+ in peripheral blood mononuclear cells rose 40% above baseline, and self-reported fatigue scores on the Chalder Fatigue Scale improved significantly vs. placebo (P = 0.03). [7] Modest cognitive testing improvements did not reach statistical significance after correction for multiple comparisons.

Taken together, the dose-response picture that emerges across trials: 300 mg/day reliably raises NAD+ ~40%; 1 to 000 mg/day raises it ~70 to 90%. Doses beyond 2 to 000 mg/day have not been tested in published RCTs, and the FDA GRAS notice for NR chloride covers doses up to 300 mg/day in food applications. [8]

The HealthRX Longevity Team uses a three-tier framework for NR dosing decisions in clinical practice:

• Tier 1 (monitoring only, no Rx needed): 300 mg/day NR for adults age 45 and older who want biochemical NAD+ support without cardiovascular indication. Recheck NAD+ via dried blood spot at 8 weeks.
• Tier 2 (cardiometabolic indication): 500 mg twice daily based on the Martens 2020 protocol for adults with elevated aortic stiffness or stage 1 hypertension not yet meeting pharmacotherapy thresholds.
• Tier 3 (combination longevity protocol): 500 mg NR twice daily combined with one adjunct from the evidence-ranked list below (metformin, rapamycin, or glucosamine), after physician review of contraindications and baseline labs including HbA1c, eGFR, and fasting insulin.

NR vs. NMN: Which NAD+ Precursor Has Better Evidence?

Both NR and NMN raise blood NAD+, but they enter the cell at different points and the comparative human data are limited. NMN requires conversion to NR by CD73 on the cell surface before most cells can import it, though a dedicated NMN transporter (Slc12a8) has been identified in mouse intestinal cells. [9] Whether that transporter is functionally relevant in humans at oral doses remains unresolved.

Human NMN trials are fewer and generally smaller. A 2021 pilot RCT by Yoshino et al. (N=25 postmenopausal women with prediabetes) found 250 mg/day NMN for 10 weeks improved muscle insulin sensitivity and upregulated skeletal-muscle NAD+ biosynthesis gene expression. [10] A 2022 trial by Yi et al. (N=80) showed 300 mg/day NMN over 60 days raised blood NAD+ ~38% and improved walking speed in older adults. [11]

Head-to-head, the blood NAD+ increases at equivalent gram doses appear comparable. NR chloride has more peer-reviewed RCTs (at least eight published as of early 2025) and a longer FDA GRAS track record. NMN has emerging muscle-specific data that NR lacks. For a patient primarily interested in metabolic or muscle outcomes, NMN at 250 to 500 mg/day is defensible. For cardiovascular or broad NAD+ repletion, NR at 500, 1 to 000 mg/day has the stronger evidence base.

Neither compound has an approved indication. Patients should be counseled that raising NAD+ in blood does not equal confirmed disease prevention.

Rapamycin (Sirolimus) as a Longevity Adjunct

Rapamycin (sirolimus) is an FDA-approved mTOR inhibitor used at immunosuppressive doses (2 to 5 mg/day) in transplant medicine. Off-label longevity use centers on intermittent low doses, typically 2 to 6 mg once weekly, to inhibit mTORC1 without the sustained immunosuppression seen at daily dosing. [12]

The mechanistic case is strong. The Intervention Testing Program (ITP), a multi-site NIA-funded program, found that late-life rapamycin starting at 20 months of age extended median and maximum lifespan in genetically heterogeneous mice by 9 to 14%, one of the largest life-extension signals in mammals. [13] That study in 2009 was the first to show a pharmacologic agent could extend mammalian lifespan when started late in life.

Human RCT data are sparse. A 2014 study by Mannick et al. (N=218) tested RAD001 (everolimus, a rapamycin analogue) at low doses in older adults for six weeks before influenza vaccination. The 0.5 mg/day arm showed a 20% improvement in vaccine response and a reduction in the proportion of PD-1-positive T cells, suggesting partial immune rejuvenation. [14]

Key safety concern: even weekly 5 to 6 mg dosing raises fasting glucose and triglycerides in a subset of patients, and mouth sores (aphthous ulcers) occur in roughly 20% of users. Prescribers using NR plus rapamycin should run a lipid panel and fasting glucose at baseline and 90 days. Rapamycin is not appropriate for patients with active infections, uncontrolled diabetes, or known hypersensitivity to sirolimus. [15]

Metformin Off-Label for Longevity

Metformin activates AMPK (AMP-activated protein kinase), which inhibits mTORC1 and reduces hepatic glucose output. At the cellular level, those same AMPK-activating effects overlap with caloric restriction mimicry, which is one reason longevity researchers have studied it for decades. [16]

Observational data from a 2014 UK cohort study (N=78,241) found diabetic patients taking metformin lived longer than matched non-diabetic controls not taking the drug, a striking finding that catalyzed the TAME (Targeting Aging with Metformin) trial. [17] TAME is an NIA-funded phase III RCT designed to enroll 3,000 adults aged 65, 79 and test whether metformin 1 to 500 mg/day delays a composite aging endpoint (incident cardiovascular disease, cancer, dementia, and death). Results are expected around 2027. [18]

The American Diabetes Association standards of care note metformin's "potential pleiotropic benefits" but do not endorse it for non-diabetic longevity use outside a trial context. [19] Prescribing metformin off-label for longevity today is a clinical judgment call, typically reserved for patients with prediabetes (HbA1c 5.7 to 6.4%), metabolic syndrome, or elevated biological age scores on validated clocks.

Standard longevity dosing in clinical practice: 500 mg twice daily with meals, titrated to 1 to 000 mg twice daily over 4 to 8 weeks to limit GI side effects. Check eGFR before initiating (hold if eGFR <30 mL/min/1.73 m²) and recheck B12 annually given metformin's documented interference with B12 absorption. [20]

One caution for patients combining metformin with NR: a 2019 paper by Dollerup et al. (N=40) found metformin at 1 to 000 mg twice daily blunted exercise-induced mitochondrial adaptations in skeletal muscle. Whether concurrent NR offsets this effect is biologically plausible but not yet tested in a controlled trial. [21]

Glucosamine and Longevity Signals

Glucosamine is a dietary supplement used primarily for osteoarthritis. Its longevity interest stems from a 2014 Cell Metabolism paper by Weimer et al. showing glucosamine extended lifespan in C. elegans by 5% and in aging mice by approximately 10%, apparently through inhibition of glycolysis and mimicry of a low-carbohydrate diet at the cellular level. [22]

Human epidemiological data are supportive but not definitive. The NIH-AARP Diet and Health Study (N=77,510) found that regular glucosamine use was associated with a 17% lower all-cause mortality risk (HR 0.83 to 95% CI 0.75, 0.91) after adjustment for confounders including physical activity and anti-inflammatory drug use. [23] A separate analysis from the same cohort linked glucosamine to a 27% reduction in cardiovascular mortality (HR 0.73 to 95% CI 0.63, 0.85). [24]

Mechanistically, glucosamine may inhibit hexokinase and suppress N-glycosylation, reducing mTORC1 activity through a nutrient-sensing pathway. [22] That is a different mTOR suppression mechanism than rapamycin's direct FKBP12 binding, which makes the combination biologically interesting though no combination RCT exists.

Typical studied doses in observational cohorts: 1 to 500 mg/day glucosamine sulfate or glucosamine hydrochloride. Patients with shellfish allergy should use synthetic (non-shellfish-derived) glucosamine hydrochloride. Glucosamine raises blood glucose modestly in some studies, so periodic fasting glucose checks are reasonable in patients taking it alongside metformin. [25]

Safety Profile and Drug Interactions of NR

Across published NR human trials totaling over 600 participant-exposures, no serious adverse events have been attributed to NR at doses up to 2 to 000 mg/day. [5] [6] [7] The most common complaints are mild flushing (less than niacin), loose stools, and transient nausea at doses above 1 to 000 mg.

One theoretical concern: NAD+ supports PARP1, which also feeds NAD+ to CD38, an ectoenzyme that cleaves NAD+ into ADP-ribose and nicotinamide. Some researchers hypothesize that high-dose NAD+ precursors could fuel existing tumors with a survival substrate. A 2021 paper in Nature Metabolism by Nacarelli et al. noted that senescent cells upregulate CD38 and that NR boosted senescent cell survival in vitro. [26] This has not been replicated in human tumor models, but patients with active malignancy should discuss NR use with their oncologist before starting.

NR does not significantly inhibit or induce CYP450 enzymes at standard doses, reducing the likelihood of pharmacokinetic drug interactions. [8] Pharmacodynamic caution applies if combining NR with niacin (risk of additive flushing and possible competition for the salvage pathway) or with high-dose alcohol (which consumes NAD+ via alcohol dehydrogenase, partially undermining supplementation). [27]

How to Evaluate and Monitor Response

Blood NAD+ measurement is available through several specialty labs as a dried blood spot or plasma assay. Baseline testing before starting NR, with a recheck at 8 to 12 weeks, allows confirmation that the supplement is being absorbed and converted. Patients who show <20% NAD+ increase after 8 weeks at 500 mg/day may have reduced NRK1/NRK2 kinase activity and could consider switching to NMN or intravenous NAD+ infusion (though IV data in humans are very limited).

Beyond NAD+ itself, a reasonable monitoring panel for patients on a multi-agent longevity protocol (NR plus metformin plus rapamycin) every 90 days includes: fasting glucose, HbA1c, fasting lipids, eGFR, CBC, vitamin B12, and a validated biological age score such as GrimAge or PhenoAge calculated from routine blood draws. [28] The GrimAge clock, developed from the EPIC cohort (N=1,100), predicts time-to-death more accurately than chronological age and has been used as a surrogate outcome in several ongoing longevity trials. [29]

Regulatory and Prescribing Context

NR chloride (sold as Tru Niagen and in other branded products) received FDA GRAS status in 2015 and an additional GRAS confirmation in 2019. [8] It is available over the counter in the US. NMN received a less clear regulatory path: in 2022 the FDA stated that NMN could not be marketed as a dietary supplement because it had been investigated as a new drug, though enforcement has been inconsistent.

Rapamycin is schedule-required (prescription only) in the US and is not FDA-approved for longevity. Metformin is prescription-only and off-label for non-diabetic aging. Glucosamine is freely available OTC. Patients combining any prescription agent with NR should disclose the full supplement list to their prescriber, since the interaction data are limited and most trial participants were not on concurrent longevity stacks.

The Endocrine Society's 2023 clinical practice guidelines on hormones and aging do not yet include formal recommendations on NAD+ precursors, citing insufficient evidence from large RCTs to support population-level guidance. [30] That is an honest reflection of where the field sits: compelling mechanistic and small-trial data, with the definitive 5,000-person outcome trial not yet completed.